Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 6/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 6/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 6/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 6/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22870048 | 1.00 | SLC6A12 (0.50) | SLC6A12SLC6A11SLC6A13HSD11B1ITGB3 | |
| SCHEMBL17008826 | 0.85 | SLC6A12 (0.43) | SLC6A12SLC6A11SLC6A13HSD11B1ITGB3 | |
| SCHEMBL30195895 | 0.84 | SLC6A12 (0.41) | SLC6A12SLC6A11SLC6A13HSD11B1GABRR1 | |
| SCHEMBL31121545 | 0.84 | SLC6A12 (0.41) | SLC6A12SLC6A11SLC6A13HSD11B1GABRR1 | |
| SCHEMBL31615208 | 0.83 | SLC6A12 (0.38) | SLC6A12SLC6A11SLC6A13CYP2C9CYP2C19 | |
| SCHEMBL30490358 | 0.80 | SLC6A12 (0.39) | SLC6A12SLC6A11SLC6A13HSD11B1GABRR1 | |
| SCHEMBL1830399 | 0.78 | — | — | |
| SCHEMBL14249941 | 0.76 | — | — | |
| SCHEMBL17294428 | 0.74 | SLC6A12 (0.38) | SLC6A12SLC6A11SLC6A13AKR1C4AKR1C3 | |
| SCHEMBL28841777 | 0.74 | LMNA (0.38) | SLC6A12SLC6A11SLC6A13CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232057-B | Synthesis method of gliclazide intermediate 3-azabicyclo [3.3.0] octane | 上海巽田科技股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115232057-A | Synthesis method of gliclazide intermediate 3-azabicyclo [3.3.0] octane | 上海巽田科技股份有限公司 | 2022-10-25 | — | — | CN | claimed |
| US-12157755-B2 | CD73 inhibitor, preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-12-03 | — | — | US | disclosed |
| CN-118786128-A | Compounds and methods for treating viral infections | 吉利德科学公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118369335-A | N1-modified pseudouridine and application thereof in mRNA synthesis | 上海吉量医药工程有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118165034-A | Nucleotide compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114539340-B | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117466964-A | Nucleoside diphosphate compound and preparation method thereof | 南京烁慧医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-115232057-B | Synthesis method of gliclazide intermediate 3-azabicyclo [3.3.0] octane | 上海巽田科技股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115232057-B | Synthesis method of gliclazide intermediate 3-azabicyclo [3.3.0] octane | 上海巽田科技股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116715700-A | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-113366008-B | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-111620909-B | Prodrug of Reidesvir, preparation method and application thereof | 广东中科药物研究有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
| CN-115232057-A | Synthesis method of gliclazide intermediate 3-azabicyclo [3.3.0] octane | 上海巽田科技股份有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232057-A | Synthesis method of gliclazide intermediate 3-azabicyclo [3.3.0] octane | 上海巽田科技股份有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-114539340-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220162253-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| US-5276169-A | Antimycotic carbonyl- and amino-substituted tetrahydrofurans | BAYER AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0538688-A1 | Substituted tetrahydrofurans, methods for their preparation, and their use as pharmaceutical compositions | BAYER AG (DE) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157755-B2 | CD73 inhibitor, preparation method therefor and application thereof | ENTPD5, ENTPD1, NT5E | SLC6A12 4004/4885SLC6A11 1129/4885SLC6A13 2053/4885 |
| US-20220162253-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ENTPD5, ENTPD1, NT5E | SLC6A12 4004/4885SLC6A11 1129/4885SLC6A13 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.